Syncona
Life sciences investor that founds, builds and funds therapeutics companies from pre-clinical to commercial stage.
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Pre-seed, Seed, Series A, Series B+, Growth
- Sector focus
- Fintech, Healthtech, Biotech & Life Sciences, Hardware & Robotics
- Cheque size
- Above €3M
- Fund size
- Undisclosed
- Founded
- 2012
- Website
- synconaltd.com
Syncona is a London Stock Exchange-listed life sciences investor managed by Syncona Investment Management Limited, which is authorised by the FCA and based in Bloomsbury, London. It builds and backs therapeutics companies, with a portfolio spanning pre-clinical, clinical, late-stage and commercial businesses in areas such as cell therapy, gene therapy and biologics.
The investment team is heavily scientific, with most members holding PhDs. In 2025 the board shifted strategy towards returning around £250m to shareholders from mature assets, while keeping a limited budget for selective new early-stage investments built on academic science and plans for a separate institutional fund.
← All investors · Is this your organisation? Request an update
More investors in the directory
The Craftory
Purpose-driven consumer packaged goods brands with category-changing potential
Symvan Capital
EIS and SEIS funds backing B2B SaaS and technology companies from seed to exit
Grafton Capital
Growth capital for European software, AI and tech-enabled businesses
Blackfinch Ventures
EIS and VCT investment in early and growth-stage UK technology businesses
The Conduit Connect
Impact-led UK startups from pre-seed to Series A in climate, health and financial resilience
TrueSight Ventures
Angel-sized cheques at pre-seed and seed, sector-agnostic, into technology companies
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.